** Biotech company Voyager Therapeutics' shares rise 6.9% to $6.18 premarket
** Wedbush analyst Yun Zhong starts coverage on stock with "outperform" rating and PT at $11; previous Wedbush analyst covering stock had a "neutral" rating and PT of $7
** The new PT is a 90.3% upside to the stock's last close
** Brokerage says positive data from VYGR's programs targeting neurodegenerative disorders, including Alzheimer's and ALS, have boosted their confidence
** Wedbush says shares are trading low, creating an "attractive investment opportunity" despite the high risks of early-stage treatments
** All ten brokerages rate the stock "buy" or higher; their median PT is $18 - LSEG
** As of last close, stock has fallen 31.5% YTD
(Reporting by Kamal Choudhury)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。